Finanzen von Evolent Health Inc (EVH)EVHEvolent Health Inc

Evolent Health, Inc. (EVH) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Clinical Solutions, accounting for 73.3% of total sales, equivalent to $507.48M. Other significant revenue streams include Evolent Health Services and Intersegment Eliminations. Understanding this composition is critical for investors evaluating how EVH navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Evolent Health, Inc. maintains a gross margin of 9.08%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1.34%, while the net margin is -4.35%. These profitability ratios, combined with a Return on Equity (ROE) of -79.90%, provide a clear picture of how effectively EVH converts its operational activities into shareholder value.

In the context of the broader market, EVH competes directly with industry leaders such as ROMA and BTBT. With a market capitalization of $529.12M, it holds a significant position in the sector. When comparing efficiency, EVH's gross margin of 9.08% stands against ROMA's 6.96% and BTBT's 26.51%. Such benchmarking helps identify whether Evolent Health, Inc. is trading at a premium or discount relative to its financial performance.

Evolent Health has shown fluctuating revenue with a recent total revenue of $652.52 million in Q2 2026, but it continues to report net losses, including a net income loss of $28.36 million in the same quarter. The gross margin has also been declining, currently at 9.08%.